GLP-1 medications (like semaglutide) and dual incretin therapies (like tirzepatide, which targets GLP-1 and GIP) have changed the conversation around obesity and metabolic health. For many people, these medications can meaningfully reduce appetite, improve blood sugar control, and support substantial weight loss—often in the range of 10–20% of body weight over time, depending on the drug, dose, and individual factors.
But they’re not “take it and forget it” treatments. The best outcomes come when you start with clear expectations, a thoughtful medical review, and a practical plan for side effects, costs, and long-term maintenance. If you’re considering GLP-1 or tirzepatide, here are the questions worth asking before you take your first dose.
1) Am I a good candidate—and for which medication?
What criteria do clinicians use?
Most prescribing guidelines consider GLP-1–based anti-obesity medications for adults with:
- A BMI ≥ 30, or
- A BMI ≥ 27 with weight-related conditions (e.g., hypertension, sleep apnea, type 2 diabetes, dyslipidemia)
Ask your clinician how your medical history fits those criteria and whether your goals are primarily weight loss, diabetes management, or both. That context matters because medication choice, dosing, and monitoring differ when the primary target is glycemic control versus obesity.
GLP-1 vs. tirzepatide: what’s the practical difference?
Tirzepatide’s dual action often translates to greater average weight loss in clinical trials compared with single-pathway GLP-1 options, but that doesn’t automatically make it “better” for you. Tolerability, cost, availability, and your current health profile should guide the decision. A good prescriber will explain why they recommend one option over another, not just what’s trendy.
2) What health conditions—or medications—could change the risk?
Are there contraindications I should know about?
You’ll want a direct conversation about red flags, particularly:
- Personal/family history of medullary thyroid cancer or MEN2 (class contraindication for many GLP-1 meds)
- Prior pancreatitis (not always an absolute no, but it’s a serious discussion)
- Gallbladder disease risk (rapid weight loss can increase gallstone risk)
- Severe reflux, gastroparesis, or significant GI disorders (these meds slow gastric emptying)
Also ask about medication interactions and practical conflicts. For example, if you take insulin or a sulfonylurea, appetite suppression plus existing glucose-lowering therapy can increase hypoglycemia risk—especially early on as your eating patterns change.
Should I get baseline labs before I start?
Many clinicians will check a baseline A1C, fasting glucose, lipids, kidney and liver function, and sometimes thyroid markers depending on your history. If you’re starting for obesity rather than diabetes, baseline labs are still useful: they help track improvements and catch issues that might affect safety or dosing.
3) What should I realistically expect in the first 12–16 weeks?
The early phase is where people either settle into a sustainable routine—or drop off because they weren’t prepared.
How fast will my dose increase?
Most GLP-1 and tirzepatide protocols rely on gradual titration to reduce nausea and other GI effects. Ask:
- What’s the titration schedule?
- What symptoms are expected versus concerning?
- When do you pause escalation or step back a dose?
If your prescriber’s approach is “start high and see what happens,” that’s a signal to slow down and reassess. Titration isn’t just a formality; it’s a major factor in whether you can stay on therapy.
What’s a good benchmark for progress?
Progress isn’t only the scale. Ask what they’ll track: waist circumference, blood pressure trends, A1C, sleep quality, cravings, binge frequency, mobility, and labs. Weight loss often comes in waves, and early plateaus don’t necessarily mean failure.
4) How do I choose a safe, well-supervised way to start?
This is where many people get tripped up—especially when online ads make it look effortless.
A practical question: Who will manage dose adjustments, side effects, and follow-up? You want an answer that includes scheduled check-ins, clear escalation guidance, and a plan for monitoring.
If you’re weighing local care options, it can help to explore GLP-1 treatment options in California so you understand what legitimate, clinician-guided programs typically include—like medical screening, ongoing supervision, and patient education—before you compare providers.
5) What side effects should I plan for—and how will I manage them?
What’s common vs. what’s urgent?
GI symptoms are most common: nausea, constipation, diarrhea, reflux, and feeling uncomfortably full. But you also want to know what warrants urgent attention (e.g., severe abdominal pain, persistent vomiting, signs of dehydration).
Ask your clinician for a simple, specific management plan. One thoughtful plan beats vague reassurance.
Here’s the one set of quick, practical questions I recommend writing down and bringing to your appointment:
- What should I eat the first week if nausea hits?
- How much protein and fluid should I target daily?
- What constipation protocol do you recommend (fiber, magnesium, polyethylene glycol, etc.)?
- When should I call you vs. seek urgent care?
- If I can’t tolerate a dose increase, what’s Plan B?
These questions move the conversation from “side effects are possible” to “here’s how we’ll handle them.”
6) What lifestyle changes actually matter with these medications?
A misconception is that GLP-1s “replace” lifestyle. In reality, they often enable healthier habits by reducing noise from hunger and cravings—but you still need structure.
Protein, strength training, and muscle preservation
With rapid weight loss, lean mass can drop if you’re not proactive. Ask for a protein target and a realistic strength-training plan. Even two to three short sessions per week can help preserve muscle and support long-term metabolic health.
Alcohol, social eating, and the “new normal”
Many people notice alcohol tolerance changes and reduced interest in certain foods. That can be a benefit, but it can also be socially and emotionally disorienting. If you have a history of emotional eating, discuss support strategies early—before frustration turns into stopping the medication abruptly.
7) What’s the long-term plan—especially if I stop?
This is the question people often forget until they’re months in.
Is this a short course or ongoing therapy?
Obesity is increasingly treated as a chronic condition, and stopping medication can lead to weight regain for many. Ask:
- How long do you typically keep patients on therapy?
- What maintenance options exist (lower dose, continued full dose, switching agents)?
- What markers would indicate it’s time to adjust the plan?
What about pregnancy, fertility, and family planning?
If pregnancy is possible in the near future, ask for specific guidance. Many clinicians recommend discontinuing GLP-1–based medications well before conception attempts. You want a timeline and a transition plan, not a vague “don’t use if pregnant.”
Closing thought: the best question is “How will we follow up?”
GLP-1 and tirzepatide treatments can be powerful tools, but they work best inside a framework: clear eligibility, careful titration, side-effect planning, strength and nutrition support, and an honest long-term strategy.
If your prescriber can’t clearly explain the “why,” the “how,” and the “what next,” keep looking. The right start isn’t just about getting the prescription—it’s about setting yourself up for results you can actually sustain.